Late-onset non-infectious pulmonary manifestations are frequent after allogeneic hematopoietic stem cell transplantation (HSCT). Among them chronic pulmonary graft versus host disease (GVHD) may lead to bronchiolitis obliterans and/or interstitial lung disease [1] . The lungs are characterized by a limited regenerative capacity. A slow repair process exists however, involving probably local endogenous progenitor cells, as well as mobilization of non-hematopoietic endothelial and mesenchymal progenitors from the bone [2, 3] .
Phenotypically differentiated donor cells have been occasionally observed in human and murine recipients' lungs after HSCT [4] [5] [6] , suggesting derivation from circulating stem cells.
We examined a cohort of sex-mismatched allogeneic HSCT patients who had undergone surgical lung biopsy for the diagnosis of a pulmonary complication at distance from the allograft. We sought to verify the existence of this pulmonary chimerism, especially in epithelial cells, using in situ hybridization for X and Y chromosomes in lung specimens.
Three hundred and thirty-five HSCT patients were admitted to the Respiratory Diseases Department of Foch Hospital, Suresnes, from 2001 to 2015. Thirteen of them underwent a surgical lung biopsy for the diagnosis of a pulmonary complication. Among these 13 patients, five were sex-mismatched, one with a male donor and four with a female donor. Tissue specimens from the four patients with female donors were analyzed with in situ hybridization for X and Y chromosomes. Hybridization failed in one case. We report clinical data and pulmonary histological analysis of the three patients with successful hybridization studies.
Prevention of GVHD consisted in all patients in treatment by cyclosporine and methotrexate. Engraftment was successful and hematopoietic chimerism was 100% of donor origin at the time of lung biopsy (Table 1) .
Patient 1 was a 47-year-old male who had undergone bone marrow HSCT for multiple myeloma after a myeloablative conditioning regimen including total body irradiation (TBI) and cyclophosphamide. Acute cutaneous GVHD occurred on day 19 after transplant, successfully treated by oral corticosteroids and ciclosporine. Corticosteroids were then progressively tapered. Nine months after HSCT and 2 weeks after complete corticosteroid cessation, he was admitted for progressive dyspnea. A chest computedtomography (CT)-scan showed extended interstitial lung disease with fibrotic opacities and diffuse ground glass opacities. Broncho-alveolar lavage (BAL) fluid analysis showed lymphocytic alveolitis with 360,000 cells/ml, 63% macrophages, 33% lymphocytes, and 2% neutrophils. lung biopsy was performed on day 297, while he was still being treated with oral cyclosporine. Patient 2 was a 59-year-old male who received allogeneic peripheral blood stem cells for acute myeloid leukemia type 4 after a myeloablative conditioning regimen including TBI and fludarabine. An acute cutaneous GVHD occurred on day 21 followed by a chronic cutaneous GVHD despite oral corticosteroid and oral mycophenolate mofetil treatment. Eight months later, when he was still being treated by mycophenolate mofetil alone, he developed a febrile dyspnea with hypoxemia. The chest CT-scan showed alveolar consolidations, ground glass opacities, and diffuse pulmonary nodules. The BAL fluid analysis showed 10,000 cells/ml with 58% macrophages, 26% lymphocytes, and 11% neutrophils. No infectious agent was detected. Pulmonary involvement persisted after some days of intravenous corticosteroids, leading us to perform a lung biopsy on day 240.
Patient 3 was a 22-year-old male who had undergone allogeneic bone marrow HSCT after a myeloablative conditioning regimen including TBI and cyclophosphamide for acute lymphoblastic leukemia with clonal surnumerous X chromosome. No acute GVHD occurred but he presented 6 months later with a chronic hepatic and pulmonary GVHD complicated by a terminal restrictive respiratory failure, leading to a double lung transplantation performed on day 1142. The chest CT-scan showed interstitial lung disease and distal constrictive bronchiolitis. At the time of lung transplantation, he was receiving oral corticosteroids and cyclosporine, and still presented complete remission of his hematological disease, with a 100% donor chimerism, ensuring there was no interference of the karyotype of his leukemia in interpretation of the results.
Clinical outcome after lung biopsy was uneventful for patient 1 and affected by a longer duration of thoracic drainage for patient 2. Ventilatory weaning was difficult after lung transplantation for patient 3 who required transient tracheotomy.
Concerning histological methods, hematoxylin-stained tissue sections of lung specimens were first examined. Then, fluorescence in situ hybridization (FISH) was performed on a 5 µm lung tissue section using a dual-color centromeric probe for chromosomes X and Y (LPE0XYc, Cytocell, Cambridge) together with fluorescent immunohistochemistry with anti-CK7 antibody (clone OV-TL 12/30, Dako, DK-2600 Glostrup, Denmark) for epithelial staining.
Histological analysis of lung specimens demonstrated alveolar damage, dystrophic and hyperplastic pneumocytes and presence of numerous macrophages in the alveolar lumen. Infectious staining and microbiological cultures remained negative in all cases.
A nonspecific interstitial pneumonia pattern was described in patient 1 and disseminated nodules constituting an In order to assess the epithelial origin of these cells, IHC with anti-cytokeratin 7 (CK7) antibody was combined with FISH for X and Y centromeres. Epithelial cells with CK7+ phenotype harboring a XX pattern were demonstrated in two cases. For the last case, although few XX cells in the alveolar wall were observed by FISH alone, we were not able to demonstrate CK7+/XX positive cells on the tissue sections analyzed with combined FISH and IHC, probably due to the rarity of these cells, which were not easy to detect using this technique (Fig. 1) .
Our report clearly demonstrates, using FISH analysis for sexual chromosomes combined with anti-cytokeratin staining in sex-mismatched allogeneic HSCT patients, that epithelial cells from donor origin are incorporated into the recipient's lungs.
This phenomenon has previously been demonstrated in murine lungs [4] with 20% epithelial chimerism detected in five mice 11 months after engraftment. Recently, it has been experimentally proven in murine lungs that nonhematopoietic bone marrow cells were the primary source of marrow-derived lung epithelial cells [7, 8] . In human lungs, epithelial chimerism was detected in 2/4 pulmonary biopsies performed on day 200 and 462 after HSCT [6] . The two patients who exhibited lung epithelial chimerism were those who received TBI during conditioning, comparing with others who received busulfan. In another study, a small cell subset between 2 and 6% of epithelial cells were detected in two HSCT recipient patients whose lungs were analyzed at autopsy; they had previously received a nonmyeloablative conditioning regimen [9] .
A contradictory study using a transgenic mouse lineage expressing the green fluorescent protein gene in lung epithelial cells was not able to detect lung alveolar epithelial cells of donor origin after excluding autofluorescence, dead cells, and contaminating blood cells [10] . Possibly the time of analysis within 3 months of transplantation was too short to observe this phenomenon and a requirement for longterm engraftment was suggested to explain this difference.
In our series, the epithelial chimerism was detected more than 6 months after the graft. This phenomenon may increase over time and it could partly explain pulmonary function recovering in some long-term allogenic stem cell transplantation survivors [11] .
We are not able to determine the precise origin of these progenitors and distinguish between bone marrow-derived hematopoietic or non-hematopoietic progenitors. However, these cells have to be located both among bone marrow and peripheral blood stem cells, as they were highlighted in patients receiving these two different types of graft.
The link between lung tissue and bone marrow cells has recently been outlined by Lefrançais et al., presenting the lung as a site of platelet biogenesis [12] . Here, despite the small number of patients, we provide the evidence that epithelial chimerism in human lungs after allogeneic HSCT exists. It may be triggered by the occurrence of lung damage, as suggested by studies in murine models, showing that lung injury is required for evidence of marrow-derived lung epithelia [13] [14] [15] . Hematopoietic stem cells could then participate in lung epithelium regeneration. However, the precise mechanisms involved in this engraftment need further clarifications before considering clinical trials with mononuclear stem cells, similar to those proposed for patients with cardiac ischemic disease [16] .
